Class / Patent application number | Description | Number of patent applications / Date published |
514164000 | With organic oxygen containing compound | 28 |
20100087403 | TOPICAL TREATMENT OF SKIN INFECTION - The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting | 04-08-2010 |
20100216749 | Combination Therapy for Neuroprotection - The present invention relates to combination therapy of a pyruvoyl derivative and an anti-oxidant, which is characterized by significant increase of the activity of microglia, inhibition of brain tissue damage by the activation of inflammatory cytokines, improvement of motor skill and recovery effect of neuronal damage. Compared to single treatment with each, this present invention provides a continuous high neuroprotective effect even after 6 hours from the onset of damage. | 08-26-2010 |
20100323996 | MEANS AND METHODS OF CONTROLLING COMMENSALES - The present invention relates to a cosmetic composition for the cleaning of the skin, said composition comprising or consisting of one or more compounds of formula (I) | 12-23-2010 |
20110086823 | DISINFECTANT - The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms. | 04-14-2011 |
20120022029 | TOPICAL PAIN RELIEVER AND METHOD OF MAKING THE SAME - A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension within a solution. The topical pain reliever may be applied to the skin of a user to provide pain relief without ingestion of the composition, thereby potentially avoiding adverse side effects. | 01-26-2012 |
20120077785 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. | 03-29-2012 |
20120094965 | Method and Formulation for Chemical Peeling - A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone. | 04-19-2012 |
20120149667 | PHARMACEUTICAL COMPOSITIONS FOR TREATING IBD - A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration. | 06-14-2012 |
20120165299 | COMBINATION MEDICAMENT - A medicament for treating inflammation of human or animal body tissues contains a steroid, typically a corticosteroid, in combination with a non-steroidal anti-inflammatory drug (NSAID), typically a cyclooxygenase (COX-1 or COX-2) inhibitor. The medicament is of a particular effectiveness in treating inflammation of and around the eyes, whether caused by infection, irritation or surgery. Further medicaments combine an NSAID with antihistamines or with mast cell stabilisers. The medicaments are particularly effective in topically-applicable form, although other forms of application should also show benefits. | 06-28-2012 |
20130065865 | BARRIER FILM-FORMING GERMICIDAL COMPOSITION FOR CONTROLLING MASTITIS - A long-lasting persistent, uniform film-forming skin protecting germicidal composition provides a long-lasting persistent barrier film when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis. A barrier film-forming agent is selected from the modified or hydrolyzed polysaccharides, particularly a hydrolyzed or modified starch, such as dextrin and maltodextrin. The barrier film-forming agent is stably solubilized in a solvent that dries to form the long-lasting persistent uniform film over the animal skin. The compositions also contain antimicrobial agents that fight against microbes that manage to penetrate the protective barrier film. Particularly, advantageous is that all the materials used are safe food additive and cost effective over the traditional barrier film forming agents. | 03-14-2013 |
20130196957 | ROLL-ON WITH HIGH SALICYLIC ACID CONTENT - The present invention relates to an assembly ( | 08-01-2013 |
20130203711 | NOVEL HERBAL OIL FOR CONTROLLING BLOOD SUGAR WITHOUT RISK OF HYPOGLYCEMEA - The invention relates to a herbal oil, for controlling blood sugar without risk of hypoglycemia, comprising of the step of (i)
| 08-08-2013 |
20130231310 | MESALAMINE SUPPOSITORY - The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository-comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m | 09-05-2013 |
20130261093 | COSMETIC COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION - A cosmetic composition in the form of an oil-in-water emulsion methods of using and producing cosmetic compositions is provided. The cosmetic composition includes an aqueous phase, an oil phase comprising a water-in-oil emulsifier, and an oil stabilizing component. The water-in-oil emulsifier is at concentration, by weight, of about 0.01% to about 6.0%, based upon weight of the composition. The oil stabilizing component includes one or both of an amphiphilic compound or a surfactant having an HLB of 13 or greater added to the aqueous phase. The oil stabilizing component is at a concentration, by weight, of about 0.01% to about 1.0%, based upon weight of the composition. The oil-in-water emulsion has an increased water load relative to water-in-oil emulsions without having an increased viscosity. | 10-03-2013 |
20130274231 | COMPOSITIONS FOR USE IN TREATMENT OF DERMATOLOGICAL DISEASES AND CONDITIONS - Compositions containing an effective dermatological disease-treating or dermatological condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle are disclosed. | 10-17-2013 |
20130296282 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. | 11-07-2013 |
20140187518 | ANTI-ITCH SCALP TREATMENT COMPOSITIONS AND COMBINATIONS - Provided herein are sulfate free and/or sodium chloride free scalp treatment compositions comprising corticosteroid, combinations containing these compositions, kits and methods, particularly for treating and/or preventing itchy scalp. | 07-03-2014 |
20140213558 | TREATMENT OF INFLAMMATORY DISEASE OR DISORDER AND COMPOSITIONS THEREFOR - Embodiments of the invention relate generally to the treatment of inflammatory diseases and disorders and, more particularly, to the treatment of symptoms of inflammatory diseases and disorders using thymoquinone (TQ) alone or in combination with other compounds, including eicosapentaenoic acid (EPA). In one embodiment, the invention provides a pharmaceutical composition suitable for the treatment of at least one symptom of an inflammatory disease or disorder, comprising: an effective amount of thymoquinone; and at least one physiologically-acceptable carrier, wherein an effective amount of thymoquinone is an amount capable of reducing or preventing the at least one symptom of the inflammatory disease or disorder. | 07-31-2014 |
20140235595 | COCRYSTALS OF PROGESTERONE - Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein. | 08-21-2014 |
20140249116 | Acne Solution - A composition for the treatment of acne includes hydrolyzed | 09-04-2014 |
20140274974 | PRESERVATIVE SYSTEM - Disclosed is a preservative or antimicrobial system, and methods for its use, that includes at least one ester of salicylic acid and glycerin or a salt thereof. | 09-18-2014 |
20140329782 | COMBINED THERAPEUTIC AGENT - The invention relates to a combined therapeutic agent, preferably for use at the prophylactic and/or therapeutic treatment of (A) in particular inflammatory diseases of the respiratory tract, in particular bronchopulmonary diseases, or of (B) in particular inflammatory diseases of the gastrointestinal tract, in particular of the intestine. The combined therapeutic agent comprises at least one vitamin D receptor agonist (VDA) and at least one further active substance, provided that the combined therapeutic agent does not contain any constituent and/or active substance from the group consisting of terpenes, monoterpenes, vasoconstrictors, alpha sympathomimetics and/or the physiologically harmless salts or derivatives thereof. | 11-06-2014 |
20150018319 | TREATMENT OF SKIN DISEASE - The present invention is drawn to compositions, systems, and methods of treating skin disease. The composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system, and in one example, the drug is acetylsalicylic acid. | 01-15-2015 |
20150119369 | Clear, Greaseless Compositions - The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products. | 04-30-2015 |
20150313916 | INFLAMMATORY DISEASE MODEL AND METHOD OF TREATMENT - Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy. | 11-05-2015 |
20150328103 | EXFOLIATING ANTI-ACNE FACE CLEANSING COMPOSITION - Methods and apparatus are provided for an exfoliating anti-acne face cleansing composition. The exfoliating anti-acne face cleansing composition includes an anti-acne active ingredient and exfoliating particles. The exfoliating anti-acne face cleansing composition further includes a high molecular weight polymer having a molecular weight at least equal to ten kiloDaltons (kD) and a moisturizer. A ratio of the high molecular weight polymer to total formula solids is between 8:100 and 12:100. A ratio of the high molecular weight polymer to an amount of moisturizer is between 4:10 and 9:10. A pH of the exfoliating anti-acne face cleansing composition is less than 5.0. | 11-19-2015 |
20160058719 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. | 03-03-2016 |
20160144038 | WATER-SOLUBLE SUPRAMOLECULAR COMPLEXES - Water-soluble supramolecular complexes formed from a water soluble block copolymer and at least one associative gelling adjuvant. The copolymer includes at least two blocks of polyethylene oxide and at least one block of polypropylene oxide. The adjuvant has a water solubility less than 0.5 g/100 ml at 20° C. When combined with water, the complexes form a transparent reversely thermo-reversible hydrogel or solution that may be repeatedly hydrated and dehydrated. The hydrogel exhibits improved gelling efficiency and enhanced solubility and/or stability for sparely soluble and insoluble pharmaceutical agents. The complexes are useful in a variety of pharmaceutical and cosmetic products and applications and may be combined with an effective amount of a cosmetic, medicament, or diagnostic in a solid dosage form. | 05-26-2016 |